A Phase 1 interventional study of HD201 and EU-Herceptin in Healthy Volunteers, sponsored by Prestige Biopharma Limited. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Prestige Biopharma Limited · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to demonstrate demonstrate the pharmacokinetic (PK) similarity of HD201 to the European (EU) and American (US) reference products Herceptin, following a single i.v. infusion of 6 mg/kg in healthy volunteers.
This is a double-blind, randomised, parallel group study, where a total of 105 healthy adult male volunteers, ≥ 18 and ≤ 55 years of age, non-smoker, will be dosed; 35 subjects per treatment group, randomly assigned to one of the 3 treatment arms.
Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy as defined by:
Male subjects who are not vasectomized for at least 6 months, and who are sexually active with non-sterile female partner [sterile female partners include women (absence of menses for 12 months prior to drug administration) or women who have had a tubal ligation, hysterectomy, or bilateral oophorectomy (at least 6 months prior to drug administration)] must be willing to use one of the following acceptable method throughout the study and for 90 days after the last study drug administration:
Exclusion Criteria:
f the following applies will be excluded from the study:
Use of medication other than topical products without significant systemic absorption:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Drug: HD201
Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Drug: EU-Herceptin
Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Drug: US-Herceptin
Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Also known as: Trastuzumab
Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Also known as: Trastuzumab
Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Also known as: Trastuzumab
Trastuzumab Serum PK Parameter (AUC0-inf)
Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin. Samples were collected from 0-1272 hours on Days 1-54.
Time frame: Up to day 54
Trastuzumab Serum PK Parameter (AUC0-last)
Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin
Time frame: Up to Day 54
Trastuzumab Serum PK Parameter (Cmax)
Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin
Time frame: Up to Day 54
| Milestone | HD201 | EU-licensed Herceptin | US-licensed Herceptin |
|---|---|---|---|
| Started | 35 | 35 | 35 |
| Completed | 33 | 33 | 32 |
| Not completed | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 | 3 |
Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin. Samples were collected from 0-1272 hours on Days 1-54.
| h*μg/mL | HD201 | EU-licensed Herceptin | US-licensed Herceptin |
|---|---|---|---|
| Trastuzumab Serum PK Parameter (AUC0-inf) | 38350.2 ± 16.0 | 37432.7 ± 16.7 | 37298.5 ± 15.5 |
Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin
| h*μg/mL | HD201 | EU-licensed Herceptin | US-licensed Herceptin |
|---|---|---|---|
| Trastuzumab Serum PK Parameter (AUC0-last) | 36587.5 ± 17.6 | 35337.1 ± 17.0 | 35619.9 ± 15.3 |
Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin
| μg/mL | HD201 | EU-licensed Herceptin | US-licensed Herceptin |
|---|---|---|---|
| Trastuzumab Serum PK Parameter (Cmax) | 148.86 ± 19.5 | 142.28 ± 15.5 | 151.10 ± 16.6 |
Collected over All (S)AEs were to be collected from the signing of the informed consent form (ICF) until the Day 54. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HD201 | 0/35 (0%) | 0/35 (0%) | 18/35 (51.4%) |
| EU-licensed Herceptin | 0/35 (0%) | 1/35 (2.9%) | 23/35 (65.7%) |
| US-licensed Herceptin | 0/35 (0%) | 0/35 (0%) | 24/35 (68.6%) |
| Event | HD201 | EU-licensed Herceptin | US-licensed Herceptin |
|---|---|---|---|
| Hand fractureInjury, poisoning and procedural complications | 0/35 | 1/35 | 0/35 |
| Event | HD201 | EU-licensed Herceptin | US-licensed Herceptin |
|---|---|---|---|
| HeadacheNervous system disorders | 11/35 | 8/35 | 7/35 |
| Infusion related reactionInjury, poisoning and procedural complications | 4/35 | 7/35 | 11/35 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/35 | 2/35 | 5/35 |
| RhinitisRespiratory, thoracic and mediastinal disorders | 1/35 | 0/35 | 4/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/35 | 4/35 | 0/35 |
| LymphopeniaBlood and lymphatic system disorders | 0/35 | 4/35 | 1/35 |
| PyrexiaGeneral disorders | 2/35 | 3/35 | 0/35 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/35 | 2/35 | 0/35 |
| Back painMusculoskeletal and connective tissue disorders | 1/35 | 1/35 | 3/35 |
| PresyncopeNervous system disorders | 0/35 | 0/35 | 2/35 |
| Age, Continuous(Years) | HD201 | EU-licensed Herceptin | US-licensed Herceptin | Total |
|---|---|---|---|---|
| Mean | 27.5 (19 to 49) | 29.6 (18 to 54) | 29.7 (19 to 52) | 28.9 (18 to 54) |
| Sex: Female, Male(Participants) | HD201 | EU-licensed Herceptin | US-licensed Herceptin | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 35 | 35 | 35 | 105 |
| Race/Ethnicity, Customized(Participants) | HD201 | EU-licensed Herceptin | US-licensed Herceptin | Total |
|---|---|---|---|---|
| Asian | 5 | 7 | 6 | 18 |
| Black or African American | 0 | 1 | 1 | 2 |
| Native Hawaiian or other Pacific | 0 | 1 | 0 | 1 |
| White | 29 | 24 | 23 | 76 |
| Other | 1 | 2 | 5 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2019 to primary completion in Aug 2019, 4 months.
Results were first posted in Jul 2026, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab
Prestige Biopharma Limited